Tags: Repurposing
- addf access
- aducanumab
- agenebio
- alzecure foundation
- amylyx
- amyotrophic lateral sclerosis
- amyvid™
- apoe
- asceneuron
- axxam
- batten disease
- benefit
- beta-amyloid
- bill gates
- biogen
- biomarkers
- birax
- blog
- caregiving
- cerebrospinal fluid csf
- chronic traumatic encephalopathy cte
- clinical trials
- cognitive vitality
- cohbar
- combination therapy
- comparative effectiveness
- concussions
- conference
- connoisseur's dinner
- cypralis
- diagnostics accelerator
- drug discovery
- early-onset alzheimer's
- epigenetics
- fall luncheon
- frontotemporal dementia
- genetics
- giving tuesday
- gliacure
- great ladies luncheon
- harrington discovery institute
- hope on the horizon
- inflammation
- klogene therapeutics
- lewy body dementia
- ltd.
- m3 biotechnology
- medicare
- melvin r. goodes prize
- memories matter
- mild cognitive impairment
- misfolded proteins
- mitochondria & metabolic function
- mri
- multiple scleroris
- neuroimaging
- neurolucent
- neuroprotection
- neurotherapia
- neurotransmitters
- new staff
- new trustees
- nyc marathon
- oryzon genomics
- partnership
- pet scan
- pharmatrophix
- policy
- prevention
- prion disease
- proteostasis
- psychogenics
- repurposing
- rexceptor
- rodin therapeutics
- runners for alzheimer's research
- supplements
- tau
- tdp-43
- tetra discovery partners
- traumatic brain injury
- vascular
- vascular dementia
- venture philanthropy
- vivreon biosciences
- world alzheimer's day
- year in review
announcements
May 10, 2019
$7.1 Million in New Funding Illustrates the ADDF’s Strong Support of a Diverse Pipeline
The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.
announcements
September 21, 2018
19th International Conference on Alzheimer’s Drug Discovery Highlights Multiple Approaches
The conference, organized by the Alzheimer's Drug Discovery Foundation, focused on gene therapy and alternative modalities for neurodegenerative diseases, progress in developing novel drugs, as well as the need for new biomarkers.
announcements
September 13, 2018
$2.3 Million in New Funding Focused on Novel Biomarkers and Treatments
The Alzheimer's Drug Discovery Foundation (ADDF) announces funding for a novel biomarker and two Phase I clinical studies.
blog
April 28, 2017
Trial of First Broad-Spectrum Drug for Neurodegeneration Seeking Volunteers
ADDF grantee Dr. Raymond Scott Turner is recruiting patients for a phase 2 trial of nilotinib—a leukemia drug being tested for treating Alzheimer’s.
announcements
April 20, 2017
ADDF-Funded Scientists Discover Two Repurposed Drugs With Promise for Alzheimer’s and FTD
A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.
blog
February 21, 2017
Closing in on a Cure: Dr. Michela Gallagher and AGB101
Dr. Michela Gallagher of Agenebio is developing AGB101, which can potentially prevent mild cognitive impairment from progressing to Alzheimer's disease.
announcements
September 29, 2016
New Clinical Trial Will Test Cancer Drug as Alzheimer’s Treatment
Dr. Howard Fillit, the ADDF's Founding Executive Director and Chief Science Officer, says: "The ADDF is proud to support a clinical trial that holds such promise for Alzheimer's patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer's."
announcements
July 30, 2015
Grantees at Lou Rovo Center for Brain Health Recruiting for New Alzheimer’s Disease Trial
Cleveland Clinic Lou Ruvo Center for Brain Health is recruiting participants for a trial to determine if treatment with rasagiline improves brain glucose metabolism and memory.
announcements
January 28, 2015
New Approach to Delay Alzheimer’s Dementia Onset to Be Tested in Phase-3 Clinical Trial
The ADDF announced today a grant to AgeneBio in support of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment.
announcements
June 26, 2014
Leading Foundations Publish Recommendations to Accelerate Drug Repurposing
A peer-reviewed publication from the ADDF and The Michael J. Fox Foundation for Parkinson’s Research offers strategic insight on how organizations can advance the repurposing of FDA-approved drugs for treating neurodegenerative diseases.
blog
June 5, 2014
An Alzheimer’s Treatment in Your Medicine Cabinet?
A recent New York Times Op-Ed highlights that, while it's possible to "repurpose" available drugs to treat patients, we don't test them because "no one stands to make money."
blog
May 23, 2014
Will the First Alzheimer’s Treatment Be a Repurposed Drug?
Dr. Jeffrey Cummings talks about the promise repurposed drugs offer to people with Alzheimer's and other dementias.
announcements
May 2, 2014
Alzheimer’s Drug Discovery Foundation Raises $1.1M for New Clinical Trial in Alzheimer’s
The ADDF raised more than $1.1 million at its Eighth Annual Connoisseur's Dinner to go to Jeffrey Cummings, MD in support of a clinical trial for a repurposed drug for treating Alzheimer's disease.
announcements
January 24, 2014
Foundations Partner on $3M Initiative to Accelerate Research + Discover Treatments for Alzheimer’s
The ADDF and the Alzheimer’s Society (UK) announced a new partnership that intends to fund projects up to $1.5 million each focused on drug repurposing.
Alzheimer's Drug Discovery Foundation
A GuideStar-Rated Charity
New York, NY 10019
info@alzdiscovery.org
212.901.8000
© Copyright 2024. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3).